CHMP fandt grund til betænkelighed ved, at der ikke var tilstrækkelig dokumentation for, at injektion af Advexin i Li- Fraumeni- tumorer var til gavn for patienterne.
The CHMP was concerned that there was not enough evidence to show that the injection of Advexin into Li-Fraumeni tumours led to benefits for patients.